These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 25218901)
1. Synergistic effects of NOD1 or NOD2 and TLR4 activation on mouse sickness behavior in relation to immune and brain activity markers. Farzi A; Reichmann F; Meinitzer A; Mayerhofer R; Jain P; Hassan AM; Fröhlich EE; Wagner K; Painsipp E; Rinner B; Holzer P Brain Behav Immun; 2015 Feb; 44():106-20. PubMed ID: 25218901 [TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells. Tada H; Aiba S; Shibata K; Ohteki T; Takada H Infect Immun; 2005 Dec; 73(12):7967-76. PubMed ID: 16299289 [TBL] [Abstract][Full Text] [Related]
3. Selective NOD1 agonists cause shock and organ injury/dysfunction in vivo. Cartwright N; Murch O; McMaster SK; Paul-Clark MJ; van Heel DA; Ryffel B; Quesniaux VF; Evans TW; Thiemermann C; Mitchell JA Am J Respir Crit Care Med; 2007 Mar; 175(6):595-603. PubMed ID: 17234906 [TBL] [Abstract][Full Text] [Related]
4. Nod2 and Rip2 contribute to innate immune responses in mouse neutrophils. Jeong YJ; Kang MJ; Lee SJ; Kim CH; Kim JC; Kim TH; Kim DJ; Kim D; Núñez G; Park JH Immunology; 2014 Oct; 143(2):269-76. PubMed ID: 24766550 [TBL] [Abstract][Full Text] [Related]
5. Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts. Yang S; Takahashi N; Yamashita T; Sato N; Takahashi M; Mogi M; Uematsu T; Kobayashi Y; Nakamichi Y; Takeda K; Akira S; Takada H; Udagawa N; Furusawa K J Immunol; 2005 Aug; 175(3):1956-64. PubMed ID: 16034140 [TBL] [Abstract][Full Text] [Related]
6. Expression of TRAF6 and pro-inflammatory cytokines through activation of TLR2, TLR4, NOD1, and NOD2 in human periodontal ligament fibroblasts. Tang L; Zhou XD; Wang Q; Zhang L; Wang Y; Li XY; Huang DM Arch Oral Biol; 2011 Oct; 56(10):1064-72. PubMed ID: 21457942 [TBL] [Abstract][Full Text] [Related]
7. RICK/RIP2 mediates innate immune responses induced through Nod1 and Nod2 but not TLRs. Park JH; Kim YG; McDonald C; Kanneganti TD; Hasegawa M; Body-Malapel M; Inohara N; Núñez G J Immunol; 2007 Feb; 178(4):2380-6. PubMed ID: 17277144 [TBL] [Abstract][Full Text] [Related]
8. Analgesic effects of chemically synthesized NOD1 and NOD2 agonists in mice. Sato T; Shikama Y; Shimauchi H; Endo Y; Takada H Innate Immun; 2011 Feb; 17(1):54-9. PubMed ID: 20083500 [TBL] [Abstract][Full Text] [Related]
9. Glycolytic reprogramming of macrophages activated by NOD1 and TLR4 agonists: No association with proinflammatory cytokine production in normoxia. Murugina NE; Budikhina AS; Dagil YA; Maximchik PV; Balyasova LS; Murugin VV; Melnikov MV; Sharova VS; Nikolaeva AM; Chkadua GZ; Pinegin BV; Pashenkov MV J Biol Chem; 2020 Mar; 295(10):3099-3114. PubMed ID: 32005665 [TBL] [Abstract][Full Text] [Related]
10. Up-regulation of NOD1 and NOD2 through TLR4 and TNF-alpha in LPS-treated murine macrophages. Takahashi Y; Isuzugawa K; Murase Y; Imai M; Yamamoto S; Iizuka M; Akira S; Bahr GM; Momotani E; Hori M; Ozaki H; Imakawa K J Vet Med Sci; 2006 May; 68(5):471-8. PubMed ID: 16757890 [TBL] [Abstract][Full Text] [Related]
11. Phenotypic Differences in Primary Murine Microglia Treated with NOD1, NOD2, and NOD1/2 Agonists. Wasmuth S; Jalilvand TV; Laffer B; Busch M; Bauer D; Langmann T; Thanos S; Kasper M; Heiligenhaus A J Mol Neurosci; 2020 Apr; 70(4):600-609. PubMed ID: 31907866 [TBL] [Abstract][Full Text] [Related]
12. Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists. Fritz JH; Girardin SE; Fitting C; Werts C; Mengin-Lecreulx D; Caroff M; Cavaillon JM; Philpott DJ; Adib-Conquy M Eur J Immunol; 2005 Aug; 35(8):2459-70. PubMed ID: 16021602 [TBL] [Abstract][Full Text] [Related]
13. Cross-tolerization between Nod1 and Nod2 signaling results in reduced refractoriness to bacterial infection in Nod2-deficient macrophages. Kim YG; Park JH; Daignault S; Fukase K; Núñez G J Immunol; 2008 Sep; 181(6):4340-6. PubMed ID: 18768892 [TBL] [Abstract][Full Text] [Related]
14. NOD2 receptors in adenopituitary folliculostellate cells: expression and function. Correa-de-Santana E; Fröhlich B; Labeur M; Páez-Pereda M; Theodoropoulou M; Monteserin JL; Renner U; Stalla GK J Endocrinol; 2009 Oct; 203(1):111-22. PubMed ID: 19608614 [TBL] [Abstract][Full Text] [Related]
16. NOD1 and NOD2 stimulation triggers innate immune responses of human periodontal ligament cells. Jeon DI; Park SR; Ahn MY; Ahn SG; Park JH; Yoon JH Int J Mol Med; 2012 Apr; 29(4):699-703. PubMed ID: 22218461 [TBL] [Abstract][Full Text] [Related]
17. The Nod2 Agonist Muramyl Dipeptide Cooperates with the TLR4 Agonist Lipopolysaccharide to Enhance IgG2b Production in Mouse B Cells. Lee SH; Park JH; Park SR J Immunol Res; 2019; 2019():2724078. PubMed ID: 31886297 [TBL] [Abstract][Full Text] [Related]
18. Enhanced induction of a histamine-forming enzyme, histidine decarboxylase, in mice primed with NOD1 or NOD2 ligand in response to various Toll-like receptor agonists. Funayama H; Huang L; Asada Y; Endo Y; Takada H Innate Immun; 2010 Aug; 16(4):265-72. PubMed ID: 19710098 [TBL] [Abstract][Full Text] [Related]
19. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Uehara A; Yang S; Fujimoto Y; Fukase K; Kusumoto S; Shibata K; Sugawara S; Takada H Cell Microbiol; 2005 Jan; 7(1):53-61. PubMed ID: 15617523 [TBL] [Abstract][Full Text] [Related]
20. Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease. van Heel DA; Hunt KA; Ghosh S; Hervé M; Playford RJ Eur J Immunol; 2006 Jun; 36(6):1629-35. PubMed ID: 16637007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]